PR Newswire
(All figures are presented in U.S. Dollars)
Highest single-quarter revenue in the Company's history with total revenue of $13.4 million in Q2 2025Adjusted EBITDA1 in Q2 2025 was $7.6 million, an increase of 148% over Q2 2024Epuris sales volumes grew 14% in the quarter compared to Q2 2024NatrobaTM sales were $7.8 million during the quarter, a sequential increase of 16% over Q1 2025Strong cash generation with $6.0 million cash from operations in Q2 2025$15.0 million debt repayment and share repurchases of $2.1 million during Q2 2025$7.0 million debt repayment subsequent to Q2 2025MISSISSAUGA, ON, July 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The Company will also hold a conference call on Friday, August 8, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Friday, August 8, 2025
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 36094#
Expires: August 15, 2025
WEBCAST:
https://app.webinar.net/2vQrZ2AYmV5
MISSISSAUGA, ON, June 13, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 2, 2025 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of RSM Canada LLP as auditor of the Company and the resolution approving the unallocated shares, rights and other entitlements under the Company's share purchase plan. A total of approximately 13 million shares, representing approximately 50.9% of the total shares outstanding were represented in person or by proxy at the meeting. The detailed results of the vote for the election of directors of Cipher is set out below:
(All figures are presented in U.S. Dollars)
Adjusted EBITDA2 in Q1 2025 was $6.2 million, an increase of 73% over Q1 2024Canadian product portfolio sales volumes grew 46% in the quarter compared to Q1 2024NatrobaTM sales were $6.7 million during the quarter, a sequential increase of 3% over Q4 2024Continued strong track record of cash generation with $4.2 million cash from operations in Q1 2025$22.0 million cash balance at the end of Q1 2025$15.0 million debt repayment subsequent to Q1 2025MISSISSAUGA, ON, May 8, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three months ended March 31, 2025.
MISSISSAUGA, ON, May 2, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2025 after the market close on Thursday, May 8, 2025. The Company will also hold a conference call on Friday, May 9, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Friday, May 9, 2025
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 69080#
Expires: May, 16, 2025
WEBCAST:
https://app.webinar.net/9dwb3Zn3Qap
MISSISSAUGA, ON, May 1, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or "the Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to commence a normal course issuer bid ("NCIB") for its common shares (the "Common Shares").
The TSX notice provides that Cipher may, during the 12-month period commencing May 5, 2025 and ending on May 4, 2026, purchase for cancellation under the NCIB up to 1,485,260 of its Common Shares, representing 10% of its public float of 14,852,604 Common Shares as of April 22, 2025 (a total of 25,622,940 Common Shares were issued and outstanding as of such date). The price which Cipher will pay for any Common Shares will be the market price at the time of acquisition.
MISSISSAUGA, ON, April 29, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") proudly announces the state of Illinois has updated its Preferred Drug Listing ("PDL") where Cipher's product Natroba™, for the treatment of scabies and head lice, has obtained preferred drug status on Medicaid state plans, and whereby its main competitive product Permethrin 5% has been downgraded to non-preferred status. As a result of this change, all Medicaid treatments for scabies and Permethrin 5% prescriptions in the state must first step through Natroba™ being the preferred treatment in Illinois.
(All figures are presented in U.S. Dollars)
Generated $8.3 million in cash during Q4 2024Natroba™ revenue was $12.0 million for the 5 months of fiscal 2024 since acquisitionFull year adjusted EBITDA1 of $15.7 million, an increase of 23% over fiscal 2023Cash at December 31, 2024 was $17.8 million or $0.70 per outstanding common shareEpuris revenue grew by 20% in fiscal 2024 compared to fiscal 2023Reactivation of a Normal Course Issuer Bid, which may include block purchases of the Company's common shares in accordance with TSX policiesMISSISSAUGA, ON, March 11, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market close on Tuesday, March 18, 2025. The Company will also hold a conference call on Wednesday, March 19, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Wednesday, March 19, 2025
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 49540#
Expires: March 26, 2025
WEBCAST:
https://app.webinar.net/A3drRqWpovk
MISSISSAUGA, ON, Dec. 10, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that MOB-015, a product for the treatment of nail fungus, did not meet the primary endpoint in the North American Phase 3 study being conducted by Moberg. The results of the North American Phase 3 study communicated by Moberg today confirm the initial indications previously informed to the market by Moberg, and accordingly announced by Cipher, on September 13, 2024.
(All figures are presented in U.S. Dollars)
Successfully closed the acquisition of the U.S. based Natroba™ business on July 26, 2024Epuris sales volumes grew 29% compared to Q3 2023, continuing growth trajectory for the fifth consecutive quarterStrong product gross margin from the acquired Natroba products of 85%Added management depth with appointment of Dr. Hamed Ghanei, Chief Business OfficerMISSISSAUGA, ON, Nov. 7, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and nine months ended September 30, 2024.
MISSISSAUGA, ON, Nov. 4, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The Company will also hold a conference call on Friday, November 8, 2024 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE:
Friday, November 8, 2024
TIME:
8:30 a.m. ET
DIAL-IN NUMBER:
416-945-7677 or 888-699-1199
REPLAY:
289-819-1450 or 888-660-6345 Code: 02131#
Expires: November 15, 2024
WEBCAST:
https://app.webinar.net/BxoA3Pp3dnP
MISSISSAUGA, ON, Oct. 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today the appointment of Hamed Ghanei as Chief Business Officer ("CBO").
Craig Mull, Interim Chief Executive Officer, commented on the appointment: "I am delighted to announce the addition of Dr. Ghanei to Cipher's executive team. Hamed's expertise in business development, including extensive experience with licensing deals and other M&A opportunities in the specialty pharmaceuticals and healthcare industries, make him an excellent fit for contributing to Cipher's next phase of substantial growth."
MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its expectations, which necessitates that Moberg inform the market about this fact.
TORONTO, Sept. 13, 2024 /CNW/ - Trading resumes in:
Company: Cipher Pharmaceuticals Inc.
TSX Symbol: CPH
All Issues: No
Resumption (ET): 10:12:56 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions
TORONTO, Sept. 13, 2024 /CNW/ - The following issues have been halted by CIRO:
Company: Cipher Pharmaceuticals Inc.
TSX Symbol: CPH
All Issues: No
Reason: Single Stock Circuit Breaker
Halt Time (ET): 10:07:56 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
(All figures are presented in U.S. Dollars)
Adjusted EBITDA was $3.1 million in Q2 2024, consistent with Q2 2023Epuris sales volumes grew 13% compared to Q2 2023, continuing its growth trajectory for the fourth consecutive quarterStrong operating cash flows of $6.2 million in Q2 2024Management changes to take effect on August 10, 2024:CFO Bryan Jacobs to transition to President, focusing on the U.S. operationsVice President, Finance Ryan Mailling appointed as Chief Financial OfficerMISSISSAUGA, ON, Aug. 8, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced its financial and operating results for the three and six months ended June 30, 2024.
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.